On November 21, 2013 the FDA announced the approval of the formidable cancer drug Crizotinib to treat ALK-positive tumors. Patients with metastatic non-small cell lung cancer who have anaplastic lymphoma kinase (ALK)-positive tumors stand to benefit greatly from the Crizotinib FDA approval. Encouraging data that demonstrated efficacious progression-free survival propelled the Crizotinib FDA approval decision. In 2011[…]
Crizotinib FDA approval benefits ALK-positive NSCLC patients
Chemotherapeutic / Anti-Neoplastic, FDA Approved 2011 Tags: Crizotinib Nov 27, 2013
COPD Patients Can Breathe Easier with Indacaterol
Anti-Asthma / COPD, FDA Approved 2011, Respiratory Tract Agent Tags: asthmaCOPD Dec 27, 2012
On July 5, 2011, Indacaterol was approved by the FDA for the treatment of chronic obstructive pulmonary disease, or COPD. Novartis announced that the brand name for this device would be the Arcapta Neohaler, and the specific approval for this once daily medication is as a long-acting beta2-adrenergic agonist for the maintenance treatment of airflow[…]
Rilpivirine Proves to be a Worthy HIV Opponent
Anti-Retroviral / Anti-HIV, Antiviral, FDA Approved 2011 Tags: EUHIV infectionvitamin D Nov 28, 2012
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor {NTRI} known as the brand name Edurant. Rilpivirine is used to treat HIV-1 infection, and it is often dispensed alongside other antiretroviral agents. As a 25 milligram tablet designed to be taken once daily with food, rilpivirine is effective at decreasing the amount of HIV infection in the[…]
Vilazodone is an SSRI that Does Not Affect Sexual Function
Antidepressant, Drug Research & Development API, FDA Approved 2011 Tags: Major Depressive DisorderserotoninSSRI Nov 27, 2012
Vilazodone is in a class of medications called selective serotonin reuptake inhibitors, or SSRIs, and is also a 5HT1A receptor partial agonist. Known as the brand name Viibryd, this medication was approved in January of 2011 to treat Major Depressive Disorder in adults. In safety studies involving 2,177 patients the most common adverse side effects[…]
Azilsartan is a Next Generation ARB Blockbuster
Drug Research & Development API, FDA Approved 2011 Tags: hypertension Nov 09, 2012
On February 25, 2011 the FDA approved Azilsartan for the treatment of hypertension. Known as the brand name Edarbi marketed by Takeda Pharmaceuticals, Azilsartan has shown to be extremely effective in clinical studies. When compared with other FDA approved medications for hypertension, particularly valsartan (Diovan) and olmesartan (Benicar), Azilsartan (Edarbi) proved to be more efficacious[…]
Patients Taking Ruxolitinib for Myelofibrosis
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approved 2011 Tags: anemiakinase inhibitor Apr 04, 2012
Ruxolitinib, CAS number 941678-49-5, is a kinase inhibitor and used to treat myelofibrosis. The condition of myelofibrosis is one that involves the bone marrow being replaced by scar tissue, therefore causing a decreased blood cell production in patients. Ruxolitinib is effective at blocking the enzymes, janus-associated kinase, or JAK 1 and 2, which causes scar[…]
Vilazodone Gets FDA Approval For Major Depressive Disorder (MDD)
Antidepressant, Drug Research & Development API, FDA Approved 2011 Tags: Major Depressive DisorderserotoninSSRI May 02, 2011
Vilazodone just received FDA approval for the treatment of major depressive depression (MDD) on January of this year. The drug will be available in 10 mg, 20 mg and 40 mg dosage forms. Major Depressive Disorder is commonly known as major depression. Unlike bipolar disorder, it is characterized by one extreme mood i.e. depressed mood.[…]
